VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma.
Thirty-two patients with by non oat cell bronchogenic carcinoma were admitted to a protocol including Cyclophosphamide (CTX) 1,000 mg/m2 i.v. day 1, VP16-213 200 mg/m2 p.o. day 1-3, every 3 weeks. Partial remissions were seen in 2 of 27 evaluable patients; 16 of 27 showed no change. Mean survival was 36.4 weeks, median survival was 38 weeks.
D002283:Carcinoma, Bronchogenic / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D011034:Podophyllotoxin / Q000031:analogs & derivatives*
D005047:Etoposide; D003520:Cyclophosphamide; D011034:Podophyllotoxin